Clinical Trial Detail

NCT ID NCT02403310
Title A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin

Selinexor

Age Groups: adult senior

No variant requirements are available.